HomeCompareCORRX vs JNJ

CORRX vs JNJ: Dividend Comparison 2026

CORRX yields 4.98% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CORRX wins by $7.7K in total portfolio value
10 years
CORRX
CORRX
● Live price
4.98%
Share price
$40.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$684.85
Full CORRX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — CORRX vs JNJ

📍 CORRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCORRXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CORRX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CORRX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CORRX
Annual income on $10K today (after 15% tax)
$423.31/yr
After 10yr DRIP, annual income (after tax)
$582.12/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $121.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CORRX + JNJ for your $10,000?

CORRX: 50%JNJ: 50%
100% JNJ50/50100% CORRX
Portfolio after 10yr
$23.9K
Annual income
$756.32/yr
Blended yield
3.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CORRX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CORRX buys
0
JNJ buys
0
No recent congressional trades found for CORRX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCORRXJNJ
Forward yield4.98%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$27.7K$20.0K
Annual income after 10y$684.85$827.78
Total dividends collected$6.0K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CORRX vs JNJ ($10,000, DRIP)

YearCORRX PortfolioCORRX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,198$498.01$10,676$355.77+$522.00CORRX
2$12,503$521.19$11,407$389.39+$1.1KCORRX
3$13,922$543.86$12,198$426.53+$1.7KCORRX
4$15,463$565.97$13,056$467.62+$2.4KCORRX
5$17,132$587.47$13,987$513.12+$3.1KCORRX
6$18,940$608.33$14,998$563.56+$3.9KCORRX
7$20,894$628.52$16,098$619.52+$4.8KCORRX
8$23,005$648.01$17,295$681.69+$5.7KCORRX
9$25,282$666.79$18,599$750.82+$6.7KCORRX
10$27,737$684.85$20,022$827.78+$7.7KCORRX

CORRX vs JNJ: Complete Analysis 2026

CORRXStock

Under normal circumstances, the fund invests at least 80% of its net assets (including the amount of any borrowings for investment purposes) in common stocks. In addition, under normal circumstances, it invests at least 80% of its net assets in equity securities of U.S. companies that have large market capitalizations (generally over $2 billion) that the fund's investment manager believes are undervalued and have the potential for long-term growth and current income. The fund may also invest up to 20% of its net assets in foreign securities.

Full CORRX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this CORRX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CORRX vs SCHDCORRX vs JEPICORRX vs OCORRX vs KOCORRX vs MAINCORRX vs ABBVCORRX vs MRKCORRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.